Pharmacy Technician Pulse

Biogen’s Aduhelm rollout goes from bad to worse

pharmaphorum

OCTOBER 21, 2021

The company’s chief executive Michel Vounatsos said he was “obviously disappointed” with the result, which he maintained resulted mainly from a lack of clarity on reimbursement which has delayed patient access. Biogen reported $1.6 million in sales for the drug in the second quarter.

Insurance

Insurance FDA

Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go

pharmaphorum

MAY 10, 2022

If lecanemab is approved it could be after the departure of Biogen chief executive Michel Vounatsos, who is leaving the company in the wake of a tumultuous few months following the approval of Aduhelm by the FDA last year.

FDA

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

pharmaphorum

JUNE 8, 2021

Biogen chef executive Michel Vounatsos defended Aduhelm in an open letter on the company’s website, saying that the company has “engaged extensively with health economists, public health experts, and payers about Aduhelm – and we have examined other recent biologic drug innovations.”

FDA

FDA Labelling

Biogen’s Aduhelm rollout goes from bad to worse

Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

Stay Connected